Meningioma overview

Jump to navigation Jump to search

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma overview

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma overview

CDC on Meningioma overview

Meningioma overview in the news

Blogs on Meningioma overview

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2] Haytham Allaham, M.D. [3]

Overview

Meningioma is a relatively common neoplasm of the central nervous system that arises from arachnoidal cells which are normally involved in the protection of the brain and spinal cord by forming a thick envelope of meninges around them. Meningioma is the most common benign tumors of the brain. About 90% of meningiomas are benign with about 2% being malignant. Meningioma was first discovered by Dr Felix Platter, a Swiss physician, in the 16th century. Meningioma may be classified according to the histological criteria of the WHO. It is classified into 3 groups: benign classic meningioma (WHO grade 1), atypical meningioma (WHO grade 2), and anaplastic malignant meningioma (WHO grade 3). Neurofibromatosis type II, cowden syndrome, and multiple endocrine neoplasia 1 are among a few conditions that are associated with meningioma. There are no established direct causes for meningioma. Meningioma must be differentiated from other diseases that cause similar presentation such as schwannoma, hemangiopericytoma, and solitary fibrous tumor. The incidence of meningioma is approximately 7.62 per 100,000 individuals in the United States. The prevalence of meningioma was estimated to be 97.5 cases per 100,000 individuals in the United States. Common risk factors in the development of meningioma are history of radiation treatment, increasing age, and female gender. There is insufficient evidence to recommend routine screening for meningioma. Meningioma could present with complications such as peritumoral brain edema, stroke, and increased intracranial pressure. The hallmark symptom of meningioma is headache. Other common symptoms of meningioma include visual impairment, hearing loss/tinnitus, focal neurological deficits, behavioral changes. Head CT scan may be diagnostic of meningioma. Some of the findings on CT scan suggestive of meningioma include edema, CSF attenuation cleft, round/elongated extraaxial mass, and hyperostosis of the adjacent skull. MRI with gadolinium is the investigation of choice for the diagnosis of meningioma. On MRI, meningioma is characterized by a homogeneous, well circumscribed, and extra-axial mass with a broad dural base. Other findings on MRI suggestive of meningioma include CSF vascular cleft sign, dural tail sign, and central necrosis or calcification that do not enhance. In asymptomatic meningiomas, the decision of surgical resection must be weighed against the possibility of conservative management according to the patient's age, clinical presentation, and the anatomical location of the tumor. The predominant therapy for meningioma is surgical resection. Current data suggest that both external beam radiotherapy and radiosurgery play an important role in the management of grade II and III meningiomas.

Historical Perspective

Meningioma was first discovered by Dr Felix Platter, a Swiss physician, in the 16th century. He described the tumor as having the shape of an acorn, fleshy, and full of holes.

Classification

Meningioma may be classified according to the histological criteria of the WHO into 3 groups: benign classic meningioma (WHO grade 1) which is made up of nine variants, atypical meningioma (WHO grade 2) which is made up of three, and anaplastic malignant meningioma (WHO grade 3) made up of three variants.

Pathophysiology

Meningioma arises from the arachnoid "cap" cells, which are normally involved in the protection of the central nervous system by forming a thick envelope of meninges around the brain and spinal cord. Because of the abundance of arachnoid cap cells in the skull base and perivenous sinuses, meningiomas are commonly found in these sites. Some meningiomas may have progesterone receptors which could make the tumor grow in size during pregnancy and in the luteal phase of the menstrual cycle. Meningiomas could be found in various locations such as sphenoid ridge, olfactory grove, falx cerebri, cerebellopontine angle, foramen magnum, ventricles, etc. Though most meningiomas are benign in nature, some may be malignant and this characterization is usually based on brain invasion, frank anaplasia, and distant metastasis. NF2, MEG2, TERT, AKT1, and NDRG2 are some of the genes that may be involved in the pathogenesis of meningioma. Some conditions could be associated with meningioma, they include neurofibromatosis type 2, cowden syndrome, nevoid basal cell carcinoma, multiple endocrine neoplasia 1 (MEN1), etc. On gross pathology, a gray, well-circumscribed, dome-shaped mass is a characteristic finding of meningioma. On microscopic histopathological analysis, meningiomas may have different characeteristics, they include mitotic figures, interdigitating processes and intercellular junctions, prominent nucleoli, necrosis, and increased cellularity.

Causes

There are no established direct causes for meningioma.

Differentiating Meningioma from other Diseases

Meningioma must be differentiated from other diseases that have similar presentation such as schwannoma, oligodendroglioma, pituitary adenoma, hemangioblastoma, etc

Epidemiology and Demographics

The prevalence of meningioma was estimated to be 97.5 cases per 100,000 individuals in the United States. The incidence of meningioma is approximately 7.62 per 100,000 individuals in the United States. Meningiomas may appear at any age, but occur most commonly among patients between 40 to 60 years. Females are more commonly affected with meningiomas than males, with the ratio being 2:1. Meningioma usually affects individuals of the African American race. Caucasian and Latin American individuals are less likely to develop meningioma.

Risk Factors

Common risk factors in the development of meningioma are history of radiation treatment, increasing age, and female gender.

Screening

There is insufficient evidence to recommend routine screening for meningioma.

Natural History, Complications and Prognosis

The median age at diagnosis of meningioma is about 65 years, with incidence increasing with advancing age. A higher annual growth rate may be seen in patients with an initial tumor diameter of greater than 25mm, MR imaging T2 signal hyperintensity, patients presenting with symptoms and edema, and male patients. Most meningiomas are single with about 1-10% being multiple. Common complications of meningioma include increased intracranial pressure, cranial nerve palsies, and hydrocephalus. Prognosis is generally good, and the survival rate of patients with meningioma mainly depends on the histological grade of the tumor and the extent of resection during surgery. A poorer survival rate may be seen in patients of advanced age, male patients, black race, malignant tumors, and patients with no initial treatment.

Diagnosis

Diagnostic Study of Choice

MRI is the gold standard test for the diagnosis of meningioma but CT is more widely available and better in urgent settings.

History and Symptoms

The hallmark symptom of meningioma is headache. Other common symptoms of meningioma include weakness, focal neurological deficits, visual impairement, hearing loss, and confusion. However, the specific clinical presentation of meningioma is determined by the exact anatomical location of the tumor.

Physical Examination

Common physical examination findings of meningioma include decreased visual acuity, hearing loss, ataxia, muscle weakness, focal neurological deficits, and more. Patients with meningioma present with different signs depending on the location of the tumor, its character, and the structures it may compress. Some patients are asymptomatic and may have not present with sign on physical examination.

Laboratory Findings

There are no diagnostic lab findings associated with meningioma.

Electrocardiogram

There are no ECG findings associated with meningioma.

X Ray

Plain radiography no longer has a role in the diagnosis or management of meningioma.

Echocardiography and Ultrasound

There are no echocardiography/ultrasound findings associated with meningioma.

CT

Head CT scan may be diagnostic of meningioma. Some of the findings on CT scan suggestive of meningioma include edema, CSF attenuation cleft, round/elongated extraaxial mass, and hyperostosis of the adjacent skull. Although MRI is the diagnostic study of choice, CT is easier to use and may be used in cases where there is a contraindication to the use of an MRI.

MRI

MRI with gadolinium is the investigation of choice for the diagnosis of meningioma. On MRI, meningioma is characterized by a homogeneous, well circumscribed, and extra-axial mass with a broad dural base. Other findings on MRI suggestive of meningioma include CSF vascular cleft sign, dural tail sign, and central necrosis or calcification that do not enhance. Meningiomas may appear different on T1 and T2-weighted sequence but with a few similarities.

Other Imaging Findings

Other imaging studies that may be helpful in the diagnosis of meningioma include magnetic resonance (MR) spectroscopy, perfusion MRI, and diffusion MRI. With MR spectroscopy, elevated levels of alanine, choline, and/or lactate could be seen. MR perfusion study could demonstrate an elevated value of relative cerebral blood volume (rCBV).

Other Diagnostic Studies

Bromodeoxyuridine labeling study may be helpful in the diagnosis of meningioma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of meningioma and a greater incidence of recurrence following surgical resection.

Treatment

Medical Therapy

In asymptomatic meningiomas, the decision of surgical resection must be weighed against the possibility of conservative management according to the patient's age, clinical presentation, and the anatomical location of the tumor.[1][2] Current data suggest that both external beam radiotherapy and radiosurgery play an important role in the management of grade II and III meningiomas.[3][4] Chemotherapeutic agents are generally not effective against meningioma.[2]

Interventions

Asymptomatic meningiomas found incidentally are usually treated expectantly. In cases with tissue edema and vascular compromise, another approach can be taken. Radiotherapy is pursued depending on the patient factor and location of the tumor. It can be done after surgery with little advantage over radiotherapy alone.

Surgery

The predominant therapy for meningioma is surgical resection. Adjunctive radiation therapy may be required among certain patients.[2] The Simpson criteria for meningioma correlates the degree of surgical resection completeness with the probability of post-surgical tumor recurrence.[2][5][6] Surgical resection is not recommended among patients with asymptomatic stable meningioma.[2]

Primary Prevention

There are no established measures for the primary prevention of meningioma.

Secondary Prevention

There are no established measures for the secondary prevention of meningioma.

References

  1. Herscovici Z, Rappaport Z, Sulkes J, Danaila L, Rubin G (2004). "Natural history of conservatively treated meningiomas". Neurology. 63 (6): 1133–4. PMID 15452322.
  2. 2.0 2.1 2.2 2.3 2.4 Meningioma. Wikipedia(2015) https://en.wikipedia.org/wiki/Meningioma Accessed on September, 25 2015
  3. Maclean J, Fersht N, Short S (2014). "Controversies in radiotherapy for meningioma". Clin Oncol (R Coll Radiol). 26 (1): 51–64. doi:10.1016/j.clon.2013.10.001. PMID 24207113.
  4. Ding D, Starke RM, Hantzmon J, Yen CP, Williams BJ, Sheehan JP (2013). "The role of radiosurgery in the management of WHO Grade II and III intracranial meningiomas". Neurosurg Focus. 35 (6): E16. doi:10.3171/2013.9.FOCUS13364. PMID 24289124.
  5. Simpson grade. Radiopaedia(2015) http://radiopaedia.org/articles/simpson-grade Accessed on September, 25 2015
  6. Simpson Grading System. Neurosurgic.com(2015) http://www.neurosurgic.com/index.php?option=com_content&view=article&id=846:simpson-grading-system-for-removal-of-meningeomas&catid=152:usefulinfo&Itemid=603 Accessed on September, 25 2015


Template:WikiDoc Sources